Pyrotinib, an irreversible pan-ErbB inhibitor, combined with capecitabine can be considered as an alternative treatment option for patients with HER2-positive metastatic BC after trastuzumab and chemotherapy [20]. This evidence concerns the gene EGFR and breast cancer.